Redeye: Xspray Pharma Q2 2023 - Defining quarters ahead
Redeye updates on Xspray Pharma following its Q2 2023 report. Focus remains on the litigation and the FDA process with Dasynoc, we leave our comments and aside minor fine-tuning maintain our view of the case.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/